Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report)’s stock price was down 0.4% on Friday . The company traded as low as $5.17 and last traded at $5.22. Approximately 102,209 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 842,200 shares. The stock had previously closed at $5.24.
Ampliphi Biosciences Stock Performance
The firm has a 50 day moving average price of $6.65 and a two-hundred day moving average price of $8.26.
About Ampliphi Biosciences
Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.
The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.
Featured Stories
- Five stocks we like better than Ampliphi Biosciences
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
